María Vieito Villar

12PUBLICATIONS
140CO-AUTHORS
Molecular targetsPredictive and prognostic markersMajor global burdens of diseaseApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 02, 2026
Type II RAF Inhibitor Tovorafenib in Recurrent/Refractory Melanoma or Other Solid Tumors With BRAF Fusions or CRAF/RAF1 Fusions or Amplification: Phase II FIRELIGHT-1 Substudy.

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Jan 10, 2026
Perceptions of social determinants influencing cancer development, outcomes, and treatment toxicity among Spanish oncologists, nurses, and pharmacists: a cross-sectional survey.

Javier-David Benítez-Fuentes, Regina Gironés Sarrió, Victoria García Samblás

|Dec 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

Elena Garralda, Charles Abbott, Alma Calahorro

|Dec 10, 2025
Impact of social determinants on the development, diagnosis, and treatment of cancer: recommended public health interventions.

Regina Gironés Sarrió, Javier David Benítez Fuentes, Victoria García Samblás

Pageof 2

Frequent Collaborators

3 joint publications

Giulia Pretelli

3 joint publications

Gabriel Schnetzler

3 joint publications

Irene Brana

3 joint publications

Elisa Fontana